• FDA permits marketing of first non-drug treatment for ADHD pharmatimes
    April 24, 2019
    The US Food and Drug Administration (FDA) has permitted marketing for the Monarch external Trigeminal Nerve Stimulation (eTNS) System, a new medical device to treat attention deficit hyperactivity disorder (ADHD).
PharmaSources Customer Service